Aaron B Skolnik Selected Research

Rivaroxaban

1/2018

Assessing Bleeding Risk in Patients With Intentional Overdoses of Novel Antiplatelet and Anticoagulant Medications.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Aaron B Skolnik Research Topics

Disease

2	Hemorrhage 01/2018 - 01/2018
2	Poisoning 01/2016 - 03/2015
1	Wounds and Injuries (Trauma) 01/2018
1	Seizures (Absence Seizure) 01/2016
1	Heart Arrest (Cardiac Arrest) 01/2016
1	Cardiogenic Shock 01/2016
1	Serotonin Syndrome (Syndrome, Serotonin) 12/2014
1	Drug-Related Side Effects and Adverse Reactions 03/2014

Drug/Important Bio-Agent (IBA)

1	Clopidogrel (Plavix)FDA Link 01/2018
1	RivaroxabanIBA 01/2018
1	AnticoagulantsIBA 01/2018
1	apixabanIBA 01/2018
1	Dabigatran FDA Link 01/2018
1	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2018
1	Bupropion (Wellbutrin)FDA LinkGeneric 01/2016
1	metaxalone (Skelaxin)FDA LinkGeneric 12/2014
1	Drug CombinationsIBA 12/2014
1	Monoamine Oxidase (MAO)IBA 12/2014
1	Therapeutic UsesIBA 12/2014
1	AntidotesIBA 03/2014
1	Intravenous Fat EmulsionsIBA 03/2014

Therapy/Procedure

1	Smart Glasses 01/2018
1	Retreatment 01/2018
1	Extracorporeal Membrane Oxygenation 01/2016
1	Length of Stay 03/2015
1	Therapeutics 03/2014